You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.
02/22/2013 09:13 AM EST
The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer.